Glargine-treated patients do not show higher cancer risk

07/29/2013 | MedPage Today (free registration)

A study in Diabetes Care showed patients who began treatment with insulin glargine had a nonsignificant 12% higher cancer incidence at one year compared with those on human neutral protamine Hagedorn insulin. Researchers also found women on glargine therapy for more than two years did not have a higher risk of breast cancer than those on NPH, while glargine-treated men had a nonsignificant 2.66-fold increased risk of prostate cancer at 12 to 24 months compared with the NPH group.

View Full Article in:

MedPage Today (free registration)

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations
Senior Manager, Compliance
Stryker
Fremont, CA
Director, Office of Device Evaluation
FDA, Center for Devices and Radiological Health
Silver Spring, MD
Director, Office of Compliance
FDA, Center for Devices and Radiological Health
Silver Spring, MD
Food & Drug Associate
Confidential
Washington, D.C., DC